On March 14, 2018 Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, reported that the Company will present new research findings from its advancing pipeline programs at the 2018 American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 14-18, 2018, at the McCormick Place Convention Center, Chicago, IL (Press release, Atreca, MAR 13, 2018, View Source [SID1234524725]). The two presentations will highlight the antibody responses in patients who have achieved positive clinical outcomes following checkpoint inhibitor therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to announce new results generated via our discovery engine, using our Immune Repertoire Capture (IRC) technology," said Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and CoFounder. "In patients having responses to cancer immunotherapy, we demonstrate that an immune system attack on tumor tissue involving anti-tumor antibodies is indeed a hallmark of such responses across diverse cancer types. We have also discovered functional anti-tumor antibodies from these patients with potential application against a variety of tumors. We are pleased to announce these findings during AACR (Free AACR Whitepaper)."
The abstracts are available in the program section of the annual AACR (Free AACR Whitepaper) meeting website, and details for the poster presentations are as follows:
Abstract Title: Increased somatic hypermutation in the immunoglobulin sequences of melanoma patients who have durable response to checkpoint inhibitor therapy (Abstract 615 / Poster 9)
Poster Session Title: Immune Response to Therapies 1
Presentation Date & Time: Sunday, April 15, 2018, 1:00 PM – 5:00 PM CT
Location: Poster Section 27, Exhibit Hall A, McCormick Place South
Abstract Title: Mining the cancer immuno-responsome: The identification of functional antitumor antibodies from patients receiving checkpoint inhibitors (Abstract 3966 / Poster 19)
Poster Session Title: Targeting Oncogenes, Tumor Suppressors, or Gene Products
Presentation Date & Time: Tuesday, April 17, 2018; 8:00 AM – 12:00 PM CT
Location: Poster Section 40, Exhibit Hall A, McCormick Place South